Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerator-based BNCT for Recurrent Head and Neck Carcinoma
NCT07058116Phase 1Recruiting
- Sponsor
- Neutron Therapeutics
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of boronophenylalanine in head and neck carcinoma (HNC), sponsored by Neutron Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started May 2025; status: recruiting.
02
Drugs
boronophenylalanine
03
Conditions
head and neck carcinoma (HNC)
Beyond the preview
Go deeper on NCT07058116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058116.